Literature DB >> 16869821

A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9.

Allan E Rettie1, Frederico M Farin, Nitasha G Beri, Sengkeo L Srinouanprachanh, Mark J Rieder, Henk H Thijssen.   

Abstract

AIMS: To determine the cause of a genotype-phenotype discordancy for acenocoumarol sensitivity. Methods A patient, highly sensitive to acenocoumarol, and previously determined to carry only a single CYP2C9*3 allele, was genotyped for additional functionally defective alleles in the CYP2C9 and VKORC1 genes. Family members were also analyzed to trace the pedigree. Results The acenocoumarol-sensitive patient was found to possess, in addition to CYP2C9*3 allele, a CYP2C9*11 allele and the VKORC1 AA diplotype which were all traced back through the parental lines. Conclusions Acenocoumarol sensitivity in this subject is the consequence of inheritance of multiple functionally defective alleles in both the CYP2C9 and VKORC1 genes. The study provides additional data in support of diminished CYP2C9 activity due to the presence of the rare *11 allele.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16869821      PMCID: PMC1885169          DOI: 10.1111/j.1365-2125.2006.02688.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Discovery of new potentially defective alleles of human CYP2C9.

Authors:  Joyce Blaisdell; Lucia F Jorge-Nebert; Sherry Coulter; Stephen S Ferguson; Su-Jun Lee; Brian Chanas; Tina Xi; Harvey Mohrenweiser; Burhan Ghanayem; Joyce A Goldstein
Journal:  Pharmacogenetics       Date:  2004-08

2.  Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

Authors:  Laurent Bodin; Céline Verstuyft; David-Alexandre Tregouet; Annie Robert; Liliane Dubert; Christian Funck-Brentano; Patrice Jaillon; Philippe Beaune; Pierre Laurent-Puig; Laurent Becquemont; Marie-Anne Loriot
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

3.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

Authors:  M Wadelius; L Y Chen; K Downes; J Ghori; S Hunt; N Eriksson; O Wallerman; H Melhus; C Wadelius; D Bentley; P Deloukas
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

4.  A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Authors:  Hsiang-Yu Yuan; Jin-Jer Chen; M T Michael Lee; Ju-Chieh Wung; Ying-Fu Chen; Min-Ji Charng; Ming-Jen Lu; Chi-Ren Hung; Chun-Yu Wei; Chien-Hsiun Chen; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

5.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Authors:  Mark J Rieder; Alexander P Reiner; Brian F Gage; Deborah A Nickerson; Charles S Eby; Howard L McLeod; David K Blough; Kenneth E Thummel; David L Veenstra; Allan E Rettie
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

6.  In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.

Authors:  Guoying Tai; Frederico Farin; Mark J Rieder; Albert W Dreisbach; David L Veenstra; Christophe L M J Verlinde; Allan E Rettie
Journal:  Pharmacogenet Genomics       Date:  2005-07       Impact factor: 2.089

7.  Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

Authors:  Barry P King; Tayyaba I Khan; Guruprasad P Aithal; Farhad Kamali; Ann K Daly
Journal:  Pharmacogenetics       Date:  2004-12

8.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors:  G P Aithal; C P Day; P J Kesteven; A K Daly
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

9.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

Authors:  Giovanna D'Andrea; Rosa Lucia D'Ambrosio; Pasquale Di Perna; Massimiliano Chetta; Rosa Santacroce; Vincenzo Brancaccio; Elvira Grandone; Maurizio Margaglione
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

10.  Identification of a novel variant CYP2C9 allele in Chinese.

Authors:  Dayong Si; Yingjie Guo; Yifan Zhang; Lei Yang; Hui Zhou; Dafang Zhong
Journal:  Pharmacogenetics       Date:  2004-07
View more
  5 in total

1.  Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.

Authors:  Aurel Constant Allabi; Yves Horsmans; Jean-Claude Alvarez; André Bigot; Roger K Verbeeck; Umit Yasar; Jean-Luc Gala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-03       Impact factor: 2.441

2.  Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity.

Authors:  Argyri Gialeraki; Christos Markatos; Elisabeth Grouzi; Efrosyni Merkouri; Anthi Travlou; Marianna Politou
Journal:  Mol Biol Rep       Date:  2009-06-28       Impact factor: 2.316

3.  CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Authors:  Stuart A Scott; Malgorzata Jaremko; Steven A Lubitz; Ruth Kornreich; Jonathan L Halperin; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

4.  VKORC1 pharmacogenomics summary.

Authors:  Ryan P Owen; Li Gong; Hersh Sagreiya; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

5.  Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats.

Authors:  Agnes Grandemange; Michael Hans Kohn; Romain Lasseur; Christiane Longin-Sauvageon; Philippe Berny; Etienne Benoit
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.